These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 2925488

  • 21. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D.
    J Clin Oncol; 2006 Sep 01; 24(25):4123-8. PubMed ID: 16896005
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2001 Jun 15; 91(12):2440-6. PubMed ID: 11413536
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Description of clinical and pathological findings, treatment and outcome of feline large granular lymphocyte lymphoma (1996-2004).
    Krick EL, Little L, Patel R, Shofer FS, Sorenmo K, Clifford CA, Baez JL.
    Vet Comp Oncol; 2008 Jun 15; 6(2):102-10. PubMed ID: 19178669
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B, Li YX, Song YW, Jin J, Liu YP, Wang WH, Wang SL, Sun YT, Yu ZH, Liu XF.
    Zhonghua Zhong Liu Za Zhi; 2006 Jan 15; 28(1):58-61. PubMed ID: 16737624
    [Abstract] [Full Text] [Related]

  • 31. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM.
    J Clin Oncol; 2005 Jul 01; 23(19):4430-8. PubMed ID: 15883411
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 01; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Non Hodgkin's lymphomas: prognostic feature of 55 patients treated with MEVAP chemotherapy.
    Mazza P, Lauria F, Gherlinzoni F, Fiacchini M, Galieni P, Tura S.
    Haematologica; 1984 Mar 01; 69(2):178-87. PubMed ID: 6429003
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 01; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.